Trial Profile

Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Mar 2021 Results assessing adverse pregnancy outcomes among women exposed to IPT in a secondary analysis, presented at the 28th Conference on Retroviruses and Opportunistic Infections
26 Nov 2020 Results assessing effect of daily 1HP on nevirapine PK in the first 90 participants who enrolled in BRIEF-TB published in the Journal of Antimicrobial Chemotherapy
11 Mar 2020 Results assessing geographic and individual risk factors for Tuberculosis or death in the Brief-Tb Trial, presented at the 27th Conference on Retroviruses and Opportunistic Infections

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com